دانلود کتاب شخصی سازی در انکولوژی زنان

Ovarian cancer (OC) is a deadly gynecological malignancy, as the major­ity of patients are diagnosed at advanced stages. In recent years, the development and clinical application of molecularly targeted therapies such as bevacizumab (Bev), poly ADP-ribose polymerase (PARP) inhibitors, and anti-programmed cell death (PD)-1 antibodies may offer potentially beneficial treatment options for patients with advanced OC. However, the clinical utility of these therapies remains limited because they are associated with specific molecular abnormalities. Therefore, the identification of reliable molecular biomarkers is necessary for appropriate patient selection for these new treatment strategies. In this review, we outline the rationale for the selection of novel targets in advanced OC and discuss new thera­peutic strategies that can be positioned as precision medicine for patients with advanced OC based on their broad mechanisms of action.